Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지

Transarterial Chemoembolization Monotherapy in Combination with Radiofrequency Ablation or Percutaneous Ethanol Injection for Hepatocellular Carcinoma

  • Xu, Chuan (Department of Interventional Radiology, Subei People's Hospital of Jiangsu Province, Clinical Hospital of Yangzhou University) ;
  • Lv, Peng-Hua (Department of Interventional Radiology, Subei People's Hospital of Jiangsu Province, Clinical Hospital of Yangzhou University) ;
  • Huang, Xin-En (Department of Chemotherapy, Jiangsu Cancer Hospital, Nanjing Medical University) ;
  • Wang, Shu-Xiang (Department of Interventional Radiology, Subei People's Hospital of Jiangsu Province, Clinical Hospital of Yangzhou University) ;
  • Sun, Ling (Department of Interventional Radiology, Subei People's Hospital of Jiangsu Province, Clinical Hospital of Yangzhou University) ;
  • Wang, Fu-An (Department of Interventional Radiology, Subei People's Hospital of Jiangsu Province, Clinical Hospital of Yangzhou University)
  • Published : 2016.09.01
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate whether combined transarterial chemoembolization (TACE) with radiofrequency ablation (RFA) or percutaneous ethanol injection (PEI) for hepatocellular carcinoma (HCC) have superior efficacy to transarterial chemoembolization (TACE) alone a retrospective review was conducted. Methods: During January 2009 to March 2013, 108 patients with hepatocellular carcinoma underwent TACE or combined therapies (TACE+RFA or TACE+PEI). The long-term survival rates were evaluated in those patients by various statistical analyses. Results: The cumulative survival rates in the combined TACE+RFA/PEI group were significantly superior to those in the TACE alone group. When the comparison among the groups was restricted to patients with two or three tumors fulfilling the Milan criteria, significantly greater prolongation of survival was observed in the combined TACE+ RFA/PEI group than in the RFA/PEI alone group. Conclusions: In terms of the effect on the survival period, combined TACE+ RFA/PEI therapy was more effective than TACE monotherapy, and also more effective than PEI or RFA monotherapy in cases with multiple tumors.

Keywords

References

  1. Benson AB, Abrams TA, Ben JE, et al (2009). NCCN clinical practice guidelings in omcology: hepatobiliary cancers. J Natl Compr Canc Netw, 7, 350-59. https://doi.org/10.6004/jnccn.2009.0027
  2. Bruix J, Sherman M, Llovet JM, et al (2001). Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the study of the Liver. J Hepatol, 35, 421-30. https://doi.org/10.1016/S0168-8278(01)00130-1
  3. Burrel M, Reig M, Forner A, et al (2012). Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolization (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol, 56, 1330-5. https://doi.org/10.1016/j.jhep.2012.01.008
  4. Chinn SB, Lee FT, Kennedy, et al (2001). Effect of vascular occlusion on radfiofrequency ablation of the liver: Results in a porcine model. AJR Am J Roentgenol, 176, 789-95. https://doi.org/10.2214/ajr.176.3.1760789
  5. Cho YK, Kim JK, Kim WT, at al (2010). Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology, 51, 1284-90. https://doi.org/10.1002/hep.23466
  6. Germani G, Pleguezuelo M, Gurusamy, et al (2010). Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocellular: a meta-analysis. J Hepatol, 52, 380-87. https://doi.org/10.1016/j.jhep.2009.12.004
  7. Golfieri R, Renzulli M, Mosconi C et al (2013). Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? J Vasc Interv Radiol, 24, 509-17. https://doi.org/10.1016/j.jvir.2012.12.013
  8. Hsu CY, Huang YH, Chiou YY, et al (2011). Comparision of radiofrequency ablation and transterial chemoembolization for hepatocellular carcinoma within the Milan criterial: a propensity score analysis. Liver Transpl, 17, 556-66. https://doi.org/10.1002/lt.22273
  9. Liapi E and Geschwind JF (2011). Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drugeluting chemoembolization? Cardiovasc Intervent Radiol, 34, 37-49. https://doi.org/10.1007/s00270-010-0012-y
  10. Llovet JM, Bru C, Bruix J (1999). Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis, 19, 329-38. https://doi.org/10.1055/s-2007-1007122
  11. Riaz A, Lewandowski RJ, Kulik L, et al (2010). Radiologicpathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol, 33, 1143-52. https://doi.org/10.1007/s00270-009-9766-5
  12. Reig M, Rimola J, Torres F et al (2013). Postprogression survival of patients with advanced hepatocellular carcinoma: rational for second-line trial design. Hepatology, 58, 2023-31 https://doi.org/10.1002/hep.26586
  13. Wilson TR, Fridlyand J, Yan Y, et al (2012). Widespread potential for growth-factor-driven resistence to anticancer kinase inhibitors. Nature, 487, 505-9. https://doi.org/10.1038/nature11249
  14. Xu C, Lv PH, Huang XE, Wang SX, et al (2015a). Efficacy of transarterial chemoembolization combined with radiofrequency ablation in treatment of hepatocellular carcinoma. Asian Pac J Cancer Prev, 16, 6159-62. https://doi.org/10.7314/APJCP.2015.16.14.6159
  15. Xu C, Huang XE, Lv PH, et al (2015b). Radiofrequency ablation in treating colorectal cancer patients with liver metastases. Asian Pac J Cancer Prev, 16, 8559-61.
  16. Xu C, Lv PH, Huang XE, et al (2015c). Radiofrequency ablation for liver metastases after transarterial chemoembolization: a systemic analysis. Asian Pac J Cancer Prev, 16, 5101-6. https://doi.org/10.7314/APJCP.2015.16.12.5101
  17. Xu C, Lv PH, Huang XE, et al (2014a). Internal-external percutaneous transhepatic biliary drainage for patients with malignant obstructive jaundice. Asian Pac J Cancer Prev, 15, 9391-4. https://doi.org/10.7314/APJCP.2014.15.21.9391
  18. Xu C, Lv PH, Huang XE, et al (2014b). Analysis of different ways of drainage for obstructive jaundice caused by hilar cholangiocarcinoma. Asian Pac J Cancer Prev, 15, 5617-20. https://doi.org/10.7314/APJCP.2014.15.14.5617
  19. Xu C, Huang XE, Wang SX, et al (2014c). Drainage Alone or Combined with Anti-tumor Therapy for Treatment of Obstructive Jaundice Caused by Recurrence and Metastasis after Primary Tumor Resection. Asian Pac J Cancer Prev, 15, 2681-4. https://doi.org/10.7314/APJCP.2014.15.6.2681
  20. Xu C, Lv PH, Huang XE, et al (2014d). Safety and efficacy of sequential transcatheter arterial chemoembolization and portal vein embolization prior to major hepatectomy for patients with HCC. Asian Pac J Cancer Prev, 15, 703-6. https://doi.org/10.7314/APJCP.2014.15.2.703
  21. Yang JD, Kim WR, Park KW, et al (2012). Model to estimate survival in ambulatory patients with hepatocellular carcinoma. Hepatology, 56, 614-21. https://doi.org/10.1002/hep.25680
  22. Yau T, Tang VY, Yao TJ, at al (2014). Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology, 146, 1691-700. https://doi.org/10.1053/j.gastro.2014.02.032